GSK PLC American Depositary Shares (Each Representing Two Ordinary Shares) (GSK) closed at $50.45 on November 13, 2026, up 0.5% from the previous close, on volume of 2,541,319 shares (30-day average 4,983,258).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 12, 2026 | Call Spread | 20-Nov-2640 : 45 C | 3,360 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
GSK Earnings Call Signals Strong Growth Despite Headwinds
TipRanks (Sun, 15-Nov 12:17 AM ET)
Measles cases rise to over 5,400 across US
Seeking Alpha News (Fri, 13-Nov 3:21 PM ET)
GSK Reports Positive CHMP Opinion for One-Dose Bexsero Booster
TipRanks (Fri, 13-Nov 6:27 AM ET)
GSK Updates NASH Drug Study as Investors Await Results
TipRanks (Thu, 12-Nov 11:30 AM ET)
GSK Reports Five PDMRs’ Share Reward Plan Acquisitions
TipRanks (Thu, 12-Nov 10:59 AM ET)
U.S. measles elimination status is at risk as regional WHO body holds annual meeting
Seeking Alpha News (Wed, 11-Nov 10:10 AM ET)
GlaxoSmithKline (GSK) Gets a Hold from Citi
TipRanks (Wed, 11-Nov 2:25 AM ET)
GSK Teams With Alamar on a 60,000-Sample Proteomics Project Spanning Immune and Neuro Signals
Market Chameleon (Wed, 4-Nov 2:18 AM ET)
Alamar Biosciences Partners with GSK on Large-Scale Proteomic Study to Advance Precision Medicine
Globe Newswire (Tue, 3-Nov 4:03 PM ET)
Globe Newswire (Mon, 2-Nov 8:00 AM ET)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
GSK PLC American Depositary Shares (Each Representing Two Ordinary Shares) trades on the NYSE stock market under the symbol GSK.
As of November 13, 2026, GSK stock price climbed to $50.45 with 2,541,319 million shares trading.
GSK has a beta of 0.06, meaning it tends to be less sensitive to market movements. GSK has a correlation of 0.00 to the broad based SPY ETF.
GSK has a market cap of $101.12 billion. This is considered a Large Cap stock.
Last quarter GSK PLC American Depositary Shares (Each Representing Two Ordinary Shares) reported $12 billion in Revenue and $1.47 earnings per share. This beat revenue expectation by $148 million and exceeded earnings estimates by $.07.
In the last 3 years, GSK traded as high as $61.70 and as low as $31.72.
The top ETF exchange traded funds that GSK belongs to (by Net Assets): AVDE, FENI, PPH, FVD, GMIE.
GSK has underperformed the market in the last year with a return of +10.5%, while SPY returned +13.4%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in GSK shares. However, GSK has outperformed the market in the last 3 month and 2 week periods, returning +2.7% and +2.8%, while SPY returned -2.8% and -0.2%, respectively. This indicates GSK has been having a stronger performance recently.
GSK support price is $49.26 and resistance is $51.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GSK shares will trade within this expected range on the day.